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Abstract
Introduction: Until 1997, Poland was one of the European countries suffering from mild/moderate iodine deficiency. In 1997, a national
iodine prophylaxis programme was implemented based on mandatory iodisation of household salt with 30 ± 10 mg KI/kg salt, obligatory
iodisation of neonatal formula with 10 µg KI/100 mL and voluntary supplementation of pregnant and breast-feeding women with addi-
tional 100–150 µg of iodine.
Our aim in this study was to evaluate the iodine status of pregnant women ten years after iodine prophylaxis was introduced.
Material and methods: A cross-sectional study was undertaken in 100 healthy pregnant women between the fifth and the 38th week of
gestation with normal thyroid function, singleton pregnancy, normal course of gestation, without drugs known to influence thyroid
function except iodine. Serum TSH, fT4, fT3, thyroglobulin (TG), anti-peroxidase antibodies (TPO-Ab), anti-thyroglobulin antibodies (TG-
Ab) and urinary iodine concentration (UIC) were determined. Thyroid volume and structure were evaluated by ultrasonography.
Results: Fifty nine per cent of studied pregnant women had a diet rich with iodine carriers and 35% obtained iodine supplements. Twenty
eight per cent appeared to have a goitre: 11 diffuse and 17 a nodular one, median goitre volume was 18.7 mL (range 6.8–29.0 mL). Median
UIC was 112.6 µg/L (range 36.3–290.3 µg/L), only 28% of women had UIC ≥ 150 µg/L. Median UIC was significantly higher in the group
receiving iodine supplements than in the group without iodine supplements: 146.9 µg/L v. 97.3 µg/L respectively, p < 0.001. Serum TSH,
fT3 and fT3/fT4 molar ratio increased significantly during pregnancy while fT4 declined. Median serum TG was normal: 18.3 ng/mL (range
0.4–300.0 ng/mL) and did not differ between trimesters. Neonatal TSH performed on the third day of life as a neonatal screening test for
hypothyroidism was normal in each case: median value was 1.49 mIU/L (range 0.01–7.2 mIU/L). Less than 3% (2 out of 68) of results were
> 5 mIU/L.
Conclusion: Iodine supplements with 150 µg of iodine should be prescribed for each healthy pregnant woman according to the assump-
tions of Polish iodine prophylaxis programme to obtain adequate iodine supply. (Pol J Endocrinol 2010; 61 (6): 646–651)
Key words: pregnancy, iodine supply, gointer prevalance
Streszczenie
Wstęp: Do 1997 roku Polska należała do grupy krajów europejskich o umiarkowanym/łagodnym niedoborze jodu. W 1997 roku wprowa-
dzono narodowy program profilaktyki jodowej, polegający na obowiązkowym jodowaniu soli kuchennej przeznaczonej do użytku do-
mowego w ilości 30 ± 10 mg KI/kg soli, obligatoryjnym jodowaniu odżywek dla niemowląt w ilości 10 µg KI/100 ml i nieobowiązkowej
suplementacji kobiet ciężarnych i karmiących o dodatkowe 100–150 µg jodu dziennie.
Celem podjętej pracy była ocena zaopatrzenia w jod kobiet ciężarnych po upływie 10 lat od wprowadzenia profilaktyki jodowej.
Materiał i metody: Przeprowadzono badanie przekrojowe w grupie 100 zdrowych kobiet ciężarnych z terenu województwa mazowie-
ckiego, będących w 5.–38. tygodniu ciąży. Kryterium włączenia były: prawidłowa czynność tarczycy, prawidłowy przebieg ciąży, ciąża
pojedyncza, nie przyjmowanie leków wpływających na tarczycę, z wyjątkiem suplementów jodu. Badano stężenie TSH, fT4, fT3, tyreoglo-
buliny (TG), przeciwciał antyperoksydazowych (TPO-Ab) i antytyreoglobulinowych (Tg-Ab) w surowicy oraz stężenie jodu w dobowym
moczu. Objętość i morfologię tarczycy oceniano ultrasonograficznie.
Wyniki: Jedynie 58% ciężarnych spożywało dietę bogatą w nośniki jodu, a 35% otrzymywało suplementy jodowe. U 28% badanych
stwierdzano wole: w 11% przypadków miąższowe, w 17% guzowate. Mediana objętości wola wynosiła 18,7 ml (zakres 6,8–29,0 ml).
Mediana stężenia jodu w moczu była 112,6 µg/l (zakres 36,3–290,3 µg/l); jedynie u 28% badanych joduria wynosiła ≥ 150 µg/l. Mediana
jodurii była znamiennie wyższa w grupie przyjmującej suplementy jodowe niż w grupie nie otrzymującej takich suplementów:
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146 µg/l v. 97,3 µg/l, p < 0,001. Stężenie TSH, fT3 i stosunek molarny fT3/fT4 wzrastały znamiennie w czasie trwania ciąży, podczas gdy
stężenie fT4 malało. Mediana TG była prawidłowa: 18,3 ng/ml (zakres 0,4–300,0 ng/ml) i nie różniła się istotnie pomiędzy trymestrami.
Noworodkowe TSH oceniane w trzeciej dobie życia w ramach skriningu niedoczynności tarczycy było w każdym przypadku prawidło-
we: mediana wynosiła 1,49 mjm./l (zakres 0,01–7,2 mjm./l) i tylko 2,9% wyników było powyżej 5 mjm./l.
Wniosek: Celem zapewnienia dostatecznej podaży jodu w okresie ciąży, każdej zdrowej kobiecie ciężarnej należy zalecać przyjmowanie
150 mg jodu dziennie, zgodnie z założeniami polskiej profilaktyki jodowej. (Endokrynol Pol 2010; 61 (6): 646–651)
Słowa kluczowe: ciąża, podaż jodu, występowanie
This study was supported by a grant from the Scientific Committee of the Medical Centre of Postgraduate Education 501-2-1-07-02/07.
Introduction
Maternal iodine deficiency (ID) during pregnancy and
lactation is a well recognised, and preventable, cause of
brain damage in the foetus and infant [1–5]. The degree
of neurodevelopmental impairment depends on the
severity of ID. In areas of severe ID ( < 20 µg/day)
5–15% of the population suffers endemic cretinism and
the general IQ of the population is 13.5 points lower
than in iodine-sufficient areas [6, 7]. In mild-moderate
ID countries in Europe, lower psychomotor develop-
ment in early infancy, as well as lower learning capaci-
ty and high prevalence of attention deficit hyperactivi-
ty disorder (ADHD) in schoolchildren, have been not-
ed [8–11]. Because the iodine status of pregnant and
breast-feeding women has an extremely important im-
pact on the health of their progeny, how to ensure ade-
quate iodine supply in this particular group has occu-
pied the attention of clinicians, professional organisa-
tions and governments [12–16]. A recent World Health
Organisation (WHO) Technical Consultant Group rec-
ommended an increase in the iodine intake for preg-
nant and lactating women to c.250 µg/day (200–300 µg/
/day) and pointed out that UIC of 150–250 µg/L indicat-
ed adequate iodine supply in pregnant women.
The aim of our study was to determine the iodine
status of pregnant women living in central Poland ten
years after the introduction of a national iodine prophy-
laxis programme.
Material and methods
One hundred and two healthy pregnant women, in-
habitants of the Warsaw region, attending the prenatal
care unit at Bielański Hospital between January 2007
and November 2008, were recruited to the study. Ex-
clusion criteria were: previous or current history of thy-
roid disease; multiple pregnancy; pathological course
of gestation; drugs known to influence thyroid gland
except iodine supplements. The participants were be-
tween the fifth and 38th week of gestation, mean age ±
± SD 31 ± 4.39 years, range 23–43. Forty six (45%) were
first time mothers and 54 (55%) had already had chil-
dren. Information about dietary habits, vitamin and
mineral supplementation was obtained from each subject.
Two women were finally excluded from the study:
one was found to have subclinical hypothyroidism, and
the other was mildly thyrotoxic in the course of multi-
nodular goitre.
The study was cross-sectional. Blood samples were
taken from each participant by standard puncture of
a cubital vein. Quantitative analyses of TSH, free T3 (fT3),
free T4 (fT4), thyroglobulin (TG), thyroid-peroxidase
antibodies (TPO-Ab) and thyroglobulin antibodies
(TG-Ab) were performed by chemiluminescent immu-
noassays (EURO/DPC, UK) using an Immulite 2000 au-
tomatic analyser. Normal ranges for analytical data
were: TSH 0.4–4.0 µIU/mL, fT4 10.4–24.4 pmol/L, fT3
1.8–4.2 pg/mL, TG 1.6–59.9 ng/mL, TPO-Ab < 35 IU/
/mL, TG-Ab < 40 IU/mL. Urine samples from 24 hour
collection were delivered by 72 participants; urinary
iodine concentration was measured by the catalytic ar-
senium-cerium method based on the Sandell-Kolthoff
reaction [17]. Ultrasonographic assessment of the thy-
roid gland was made in each case using a Medison S.A.
–9900 Prime scanner with linear transducer 5–12 MHz.
Subjects with thyroid nodules underwent fine-needle
aspiration biopsy (FNAB) according to the recommen-
dations of the Polish Group for Endocrine Tumours [18].
Neonates’ TSH was examined as part of the neonatal
screening protocol. The procedure was based on deter-
mination of TSH in dried blood spots obtained by heel
puncture three days after birth. Results above 15 mIU/L
were indicative of hypothyroidism.
All statistical analyses were performed using Statis-
tica 7.0 software. Usual statistics: mean, standard devi-
ation and median have been used to describe the data.
Distributions of variables were tested according to Kol-
mogorov-Smirnov and Lilliefors tests. The distributions
of fT3, fT4, UIC and thyroid volume were log-normal.
TSH presented gamma distribution and distribution of
TG was exponential. In the analysis of TG and TSH one-
parametric transformation of Box-Cox was applied to
obtain normal distribution. Data was analysed by one-
way and two-way ANOVA with NIR post hoc test for
comparison between trimesters. Mann-Whitney and
Kruskal-Wallis tests were used to analyse non-normal-
ly distributed unpaired data. Correlations were mea-
sured with the Spearman rank correlation coefficients.
P < 0.05 was considered significant.
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The study was approved by the Ethical Committee
of the Medical Centre of Postgraduate Education and
informed consent was obtained from all participants.
Results
One hundred healthy euthyroid pregnant women were
finally enrolled on the study. Of them, 18 appeared to
be positive for thyroid antibodies: 13 for TPO-Ab, nine
for TG-Ab (four for both of them).
Twenty eight subjects were diagnosed by ultra-
sonography as having a goitre: 11 had a diffuse goitre
and the other 17 a nodular one. The median volume of
goitre was 18.7 mL, (range 8.4-29.0 mL, mean ± SD 19.7 ±
± 5.1). Age, parity, presence of thyroid antibodies and
UIC did not influence thyroid volume. In 15 women,
FNAB was undertaken and the cytological results of
18 nodules were obtained: all were benign.
The dietary habits and supplementation with vitamins
and minerals in the study group are set out in Table I:
only 35% of pregnant women received iodine supple-
ments. The amount of iodine in the supplements was
150 µg per tablet (the usual amount of iodine in supple-
ments prepared for pregnant women).
Median UIC in the whole group was 112.6 µg/L
(range 36.3–290.3 µg/L, mean ± SD 123.9 ± 58.9 µg/L)
and there were no statistical differences in UIC between
trimesters (Table II). Forty two per cent of the studied
pregnant women had UIC < 100 µg/L, while only 28%
had values within the recommended range ≥ 150 µg/L
(Table III). In the group receiving iodine supplements,
median UIC was significantly higher than in the group
without iodine supplements: 146.9 µg/L v. 97.3 µg/L re-
spectively, p < 0.001.
Serum TSH, fT3 concentrations and fT3/fT4 molar ra-
tio increased significantly during pregnancy, while se-
rum fT4 concentrations declined (Table II). Similar signs
of thyroid stimulation were observed in the reference
group of 88 subjects without thyroid antibodies: increase
of serum fT3, fT3/fT4 molar ratio and decrease of fT4 (Table
II). Median serum TSH in the reference group was signif-
icantly lower than in the antibody-positive group: 0.97
mIU/mL v. 1.5 mIU/mL respectively, p < 0.0005 (Table IV).
Serum TG was examined in subjects negative for TG-
-Ab; the median value in the whole group was 18.3 ng/
/mL (range 0.4–300 ng/mL, mean ± SD 27.7 ± 46.0 ng/
/mL) and it did not differ significantly between trimes-
ters. Median serum TG was significantly higher in the
group with goitre than in the group with normal thy-
roid: 25.9 ng/mL v. 15.3 ng/mL respectively, p < 0.004.
In the whole studied group, there was a weak positive
correlation between thyroid volume and serum TG con-
centration; r = 0.29, p < 0.01 and positive correlation
between TSH and fT3/fT4 index; r = 0.3, p < 0.002.
The information about neonates’ TSH was obtained
in 68 cases. All the results were normal: median neo-
nates’ TSH was 1.49 mIU/mL (range 0.01–7.2 mIU/mL,
mean ± SD 1.87 ± 1.58 mIU/mL). Two results (2.9%)
were above 5 mIU/mL: 5.8 mIU/mL and 7.2 mIU/mL.
The mother of the first of these two children was exam-
ined in the first trimester: her fT4 was 18.3 pmol/L, TSH
1.2 mIU/mL, TG 14.9 ng/mL, thyroid ultrasound was
normal, she was negative for thyroid antibodies, did
not obtain iodine supplements and data concerning UIC
was not obtained. In the second case, the mother was
examined in the third trimester: her fT4 was 12.0 pmol/
L, TSH 1.7 mIU/mL, TG 25.1 ng/mL, thyroid antibodies
were absent, UIC 196 µg/mL, she had a diffuse goitre
measuring 25 mL and she obtained iodine supplements.
The median TSH of neonates whose mothers obtained
iodine supplements during pregnancy did not differ
from those whose mothers were not supplemented (1.57
mIU/mL v. 1.33 mIU/mL respectively), p = NS.
Discussion
Poland is one of the European countries which has his-
torically suffered from iodine deficiency. Iodine prophy-
laxis was first introduced in our country in 1935 but
twice interrupted, first in the period 1939-47 because of
Table I. Dietary habits, supplementation with vitamins/minerals and iodine in 100 pregnant women
Tabela I. Nawyki żywieniowe i suplementacja witaminowo-mineralna w grupie 100 kobiet ciężarnych
Pregnancy trimester Diet rich Vitamin/minerals Vitamin/minerals
with iodine supplementation  and iodine supplementation
n %  n %  n %
1st n = 32   17 53    8 25   10 31
2nd n = 36   19 53   11 31   14 39
3rd n = 32   23 72   16 50   11 34
All n = 100   59 59   35 35   35 35
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Table II. Laboratory and sonographic data of 100 women according to trimesters of pregnancy and antibody status
Tabela II. Charakterystyka laboratoryjna i ultrasonograficzna 100 kobiet ciężarnych z uwzględnieniem kolejnych trymestrów
ciąży i obecności przeciwciał tarczycowych
Data   1st trimester   2nd trimester 3rd trimester ANOVA
Mean ± SD Median    mean ± SD Median    Mean ± SD Median
All
TSH [µIU/mL] 0.91±0.56 0.85 1.27±0.7 1.12 1.48±0.99 1.17 p < 0.004I
fT4 [pmol/L] 16.0±2.0 15.9 14.3±1.7 14.0 13.6±1.4 13.4 p < 0.0000
II
fT3 [pg/mL] 3.4±0.7 3.3 3.9±0.7 3.8 4.0±0.5 3.9 p < 0.002
III
fT3/fT4 0.33± 0.1 0.31 0.42±0.1 0.41 0.45±0.1 0.45 p < 0.00001
IV
TG [ng/mL] 33.7±56.3 20.8 30.9±53.4 21.3 17.9±13.9 14.4 p = 0.2
Urine iodine  [µg/L] 112.0±60.2 100.8 137.3±63.6 128.3 122.3±52.3 109.8 p = 0.2
Thyroid volume [mL] 14.2±4.1 13.9 14.4±5.2 14.9 13.6±5.4 12.2 p = 0.7
Ab negative
TSH [µIU/mL] 0.86±0.5 0.85 1.22±0.7 1.1 1.09±0.46 1.09 p = 0.06
fT4 [pmol/L] 15.9±2.0 15.6 14.2±1.8 14.0 13.7±1.6 13.8 p < 0.0003
V
fT3 [pg/mL] 3.4±0.6 3.5 3.9±0.8 3.8 3.9±0.5 3.9 p < 0.001
VI
fT3/fT4 0.32±0.03 0.31 0.43±0.06 0.39 0.45±0.05 0.43 p < 0.00001
VII
TG [ng/mL] 35.7±58.2 21.2 32.4±55.0 21.9 15.8±11.7 13.9 p = 0.07
Urine iodine [µg/L] 110.8±53.9 109.3 124.8±50.1 123.6 126.2±48.8 112.9 p = 0.4
Thyroid volume [mL] 13.8±3.8 13.4 14.5±5.4 14.9  13.5±5.5 12.1 p = 0.8
I1st v. 2nd p < 0.01, 1st v.3rd p < 0.001, 2nd v. 3rd p = 0,3, NIR test; II1st v.2nd p < 0.0001, 1st v. 2nd p < 0.00001 , 2nd v. 3rd p = 0.1 NIR test; III1st v. 2nd
p < 0.001, 1st v. 3rd 0.0001, 2nd v.3rd p = 0.5, NIR test; IV1st v. 2nd p < 0.00001, 1st v. 3rd 0.00001, 2nd v.3rd p = 0.09, NIR test; V1st v.2nd p < 0.001, 1st
v.3rd p < 0.0001, 2nd v.3rd p = 0.3, NIR test; VI1st v. 2nd p < 0.002, st v. 3rd p < 0.001, 2nd v.3rd p-0.6, NIR test; VII1st v. 2nd p < 0.00001, 1st v. 2nd p <
0.00001, 2nd v.3rd p = 0.08, NIR test
Table IV. Data of 100 pregnant women stratified by antibody status
Tabela IV. Charakterystyka 100 kobiet ciężarnych z uwzględnieniem obecności przeciwciał tarczycowych
Ab negative  (n = 82) Ab positive (n = 18) ANOVA
Mean ± SD Median (range)     Mean ± SD Median (range)
Age 30.9±4.5 31 (23–43) 31.8±4.0 32 (26–39) p = 0.6
TSH [µIU/mL] 1.1±0.6 0.9 (0.02–3.6) 1.9±1.1 1.5 (0.5–4.4) p < 0.0005
fT4 [pmol/L] 14.6±2.0 14.5 (9.6–21.4) 14.4±1.5 13.8 (12.3–17.9) p = 0.7
fT3 [pg/mL] 3.7±0.7 3.6 (2.2–5.7) 3.9±0.7 3.9 (2.6–5.3) p = 0.6
 fT3/fT4 0.39±0.1 0.38 (0.2–0.7) 0.41±0.1 0.43 (0.3–0.6) p = 0.8
TG [ng/mL] 28.6±48.0  18.8 (0.9–300) 19.7±18.0 14.7 (0.4–53.7) p = 0.8
Urine iodine [µg/L] 120.2±50.7 114.8 (36–245)  141.6±86.6 102 (43–290) p = 0.7
Thyroid volume 13.9±4.9 13.2 (6.8–29) 14.2±5.0 13.9 (7.2–24.7) p = 0.8
Table III. Median urine iodine concentration in 76 pregnant women
Tabela III. Mediana stężenia jodu w moczu w grupie 76 kobiet ciężarnych
Urine iodine concentration µg/L
< 50 50–99 100–149 150–250 251–300
 n      % n % n % n % n %
6       8 26 34  23 30 18 24 3 4
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the Second World War, and again from 1980 due to eco-
nomic reasons. The results of the nationwide epidemi-
ological survey conducted in 1992–1993 [19] and the
European survey led in 1994–1995 [20] showed that
more than 90% of Polish territory suffered from mod-
erate ID with less than 10%, the area along the Baltic
Sea, fulfilling the criteria of mild ID. Iodine prophylaxis
based on iodisation of household salt was reestablished
in 1986 as a voluntary model with 25 ± 10 mg KI/kg
salt, and in 1997 as a mandatory model with 30 ± 10 mg
KI/kg salt. The mandatory model also comprises oblig-
atory iodisation of neonatal formula with 10 µg KI/ 100
mL. It strongly recommends voluntary supplementa-
tion of pregnant and breastfeeding women with an
additional 100–150 µg of iodine daily given in tablets as
potassium iodide or as a component of multivitamin/
/mineral pills.
Before implementation of the mandatory salt iodis-
ation programme, the prevalence of goitre was 28-56%
in schoolchildren aged 6–9 and 25% in adults [21–24].
In pregnant women, goitre in the third trimester
reached 80% in some areas [25]. In 80–90% of pregnan-
cies UIC was < 150 µg/L, mean 60 µg/L [26, 27]. The
frequency of TSH > 15 mIU/L among neonates was
3.3% [28]. By 2003, goitre occurrence in schoolchildren
had diminished to < 5%, meaning that endemic goitre
had been eradicated and the prevalence of TSH >
> 15 mIU/L in neonates declined to 0.55% [28–30]. In 2003,
WHO, UNICEF and ICCIDD recognized Poland as
a country of sufficient iodine supply [31]. However, ob-
servations of pregnant women since iodine prophylax-
is introduction are still insufficient; it has been demon-
strated that only 50% of subjects are supplemented with
iodine and the prevalence of goitre declined only to 19%
in some areas [32]. Our study showed that although the
iodine status of pregnant women ten years after iodine
prophylaxis introduction had improved greatly, it is still
unsatisfactory. Median UIC was 112.6 µg/L but in only
28% of cases was within the recommended WHO level
≥ 150 µg/L. While 70% of women obtained multivita-
min pills enriched with minerals, only half of them con-
tained iodine. In the group of 35 women supplement-
ed with iodine, median UIC was 146.9 µg/L, very close
to the recommended value. In harness with insufficient
UIC, our study noted signs of excessive thyroid stimu-
lation, such as preferential T3 secretion and increasing
TSH concentration, which correlated positively to fT3/
/fT4 index. Because 18% of our study group demonstrat-
ed the presence of thyroid antibodies (higher than the
5–12% found in other studies) [2, 33], we analysed lab-
oratory data separately in the group negative for TPO-
Ab and TG-Ab to eliminate their possible influence on
thyroid economy. The same tendency of preferential
T3 secretion was observed in this reference group,
although serum TSH did not differ between trimesters
(p = 0.06). The high prevalence of thyroid antibodies in
our study can be attributed to the age of participants,
mean 31 years, which is relatively advanced for preg-
nant women, but reflects the social reality for women
living in a big city.
Serum TG, a very sensitive indicator of iodine in-
sufficiency and excessive thyroid stimulation [34], did
not differ between trimesters. Nevertheless, we found
weak positive correlation between serum TG and thy-
roid volume.
The prevalence of goitre in the analysed group of
pregnant women was 28%, one third of what it had been
before the introduction of mandatory iodine prophy-
laxis, but still high. However, the median goitre volume
was 18.7 mL and in most women it was not accompa-
nied by any clinical symptoms. We could not demon-
strate any association between thyroid volume and age,
parity, presence of thyroid antibodies or UIC.
No case of neonatal TSH > 15 mIU/L was found,
and only 2.9% of neonatal TSH results were above
5 mIU/L. According to the criteria for the absence of
iodine deficiency, less than 3% of the neonatal TSH
should be above 5 mIU/L. A percentage of between 3%
and 19.9 % indicates mild iodine deficiency, 20–39.9%
relates to moderate deficiency, and above 40% is severe
iodine deficiency.
Our results clearly demonstrate that the assumptions
of the Polish model of iodine prophylaxis are valid but
they have not been fully realised. Educational efforts
must be made among both pregnant women and obste-
tricians to encourage more iodine carriers in the diet and
to prescribe iodine in the form of potassium iodine tab-
lets or iodine-containing pre-natal multivitamin prepa-
rations, which are freely available. The problem of the
infrequent use of iodine supplements by pregnant wom-
en in European countries has been reported previously:
at present, only 13–50% of pregnant women in Europe
receive iodine-enriched supplements [15, 16, 35].
The Polish iodine prophylaxis programme takes into
account the WHO recommendations concerning limi-
tations on salt intake. The Polish Council for Control of
Iodine Deficiency Disorders (PCCIDD) prepares the
protocol of iodisation cattle fodder so as to provide
100–150 µg of iodine for every litre of cows’ milk. It is
clear that economic conditions will be crucial in accom-
plishing this goal.
Conclusion
Supplements containing 150 µg of iodine should be pre-
scribed for every healthy pregnant woman, and the as-
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sumptions of the Polish iodine prophylaxis programme
should be followed through to ensure adequate iodine
supply.
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